Diversified Trust Co. Buys New Stake in Bruker Corporation $BRKR

Diversified Trust Co. acquired a new stake in Bruker Corporation (NASDAQ:BRKR) in the 4th quarter, HoldingsChannel reports. The fund acquired 16,716 shares of the medical research company’s stock, valued at approximately $787,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Royal Bank of Canada boosted its position in Bruker by 8.3% during the first quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after purchasing an additional 9,501 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Bruker in the 1st quarter valued at $262,000. Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after purchasing an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Bruker by 2.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after buying an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth grew its stake in Bruker by 115.0% during the 1st quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock valued at $469,000 after acquiring an additional 6,008 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. The trade was a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 11,000 shares of company stock worth $554,280. Company insiders own 27.30% of the company’s stock.

Bruker Stock Performance

Shares of BRKR opened at $33.72 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $56.22. The stock has a 50 day moving average price of $40.06 and a 200 day moving average price of $41.15. The company has a market capitalization of $5.13 billion, a price-to-earnings ratio of -224.80, a price-to-earnings-growth ratio of 2.11 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same quarter in the previous year, the company posted $0.76 EPS. The company’s quarterly revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s payout ratio is presently -133.33%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Citigroup dropped their price target on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a research report on Friday, February 13th. Guggenheim increased their price target on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Jefferies Financial Group set a $50.00 target price on shares of Bruker in a report on Thursday, February 12th. Barclays cut their price target on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Finally, Wells Fargo & Company boosted their price target on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $50.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.